San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
BOSTON and CAMBRIDGE, Mass., Oct. 20, 2014 /PRNewswire/ – The Global Alliance for Genomics and Health convened its second major meeting of 2014 on Saturday, bringing together more than 250 international leaders to collaborate on the development of innovative solutions to accelerate sharing of genomic and clinical data. At their plenary meeting, held in San Diego, California, Alliance members shared progress to date and discussed next steps for the effort.
The Global Alliance is an international coalition of over 140 member organizations dedicated to improving human health by maximizing the potential of genomic medicine. The group’s diverse membership includes world-leading institutions in healthcare, research, patient and disease advocacy, life science, and information technology who are working together on open interfaces and catalytic projects to enable effective and responsible data sharing and guide this quickly evolving field. The Alliance is supported by a small number of Host Institutions, including the Broad Institute of Harvard and MIT.
“The Global Alliance is focused on developing approaches that will enable sharing of genomic and clinical data. In just over one year, we have established a vibrant international effort to accelerate progress in harmonizing regulations and ethics, methods for sharing genomic and clinical data, and approaches to privacy and security,” said David Altshuler, Chair of the Global Alliance Steering Committee and Deputy Director of the Broad Institute of Harvard and MIT. “Our members are dedicated to producing work products and to undertaking data sharing projects that break down barriers and increase learning from data.”
Following its formation in 2013, the Global Alliance has sparked collaboration that involves hundreds of stakeholders globally and released several major products, including a regulatory Framework to guide the responsible sharing of genomic and health-related data and a GA4GH Genomics API to streamline specific technical aspects of data sharing and allow for more seamless exchange globally.
The Alliance’s plenary meeting coincided with the Annual Meeting of the American Society of Human Genetics (ASHG), and the Global Alliance will also hold an information session for ASHG attendees on Monday, October 20.
“Our field is rapidly evolving, and the Global Alliance continues to be at the forefront of efforts to create harmonized approaches and catalyze projects that drive research forward,” said Cynthia Morton, President of ASHG. “We believe that this international partnership will be highly effective in unlocking potential advancements in human health, and we’re excited to contribute substantially to the capabilities, capacity, and progress of the Global Alliance in the coming years.”
In addition to highlighting best practices and developing targeted methods to advance responsible data sharing, Alliance members are advancing data sharing projects to demonstrate value and promote real-world learning. These include a global BRCA Challenge, which aims to learn from genotype and phenotype data from many studies without compromising patient privacy, thereby increasing the ability to interpret BRCA1 and BRCA2-related cancer risks. Another example is the Matchmaker Exchange project, designed to help patients and doctors grappling with rare genotypes and phenotypes to overcome siloed data, find one another through a federated architecture, and work together.
“The Global Alliance’s work will allow researchers and clinicians to tap into the power of data networks on a global scale,” said Keith Yamamoto, Vice Chancellor for Research and Executive Vice Dean of the School of Medicine at the University of California, San Francisco (UCSF), who gave opening remarks at the meeting. “The Alliance is expanding the boundaries of data sharing to improve human health, while promoting meaningful standards. The field needs this effort as we move forward and work to harness the transformational potential of biomedicine.”
On September 18, 2014 the Global Alliance adopted a Constitution to formally guide and govern the structure and membership criteria of the organization. In less than a month, more than 135 organizations of the over 200 that had originally signed a Letter of Intent have already transitioned to full members of the Global Alliance for Genomics and Health. It is expected that many more organizations and individuals will do so in the coming months.
“At a time of rapid change, the Global Alliance is coming together for our second plenary meeting in San Diego to look ahead to our next steps and achievable goals in the next few years,” said Martin Bobrow, Vice Chair of the Global Alliance Steering Committee and Emeritus Professor of Medical Genetics at the University of Cambridge. “As was evident at this critical meeting, the Global Alliance will continue to promote international collaboration to identify, develop, and promulgate innovative approaches to data sharing and to support efforts already underway.”
The Global Alliance for Genomics and Health is an international, non-profit alliance formed to help accelerate the potential of genomic medicine to advance human health. The Alliance is currently hosted by the Broad Institute of Harvard and MIT, the Ontario Institute of Cancer Research, and the Wellcome Trust Sanger Institute. Bringing together over 140 leading organizations working in healthcare, research, disease and patient advocacy, life science, and information technology, partners in the Global Alliance are working together to create a common framework of standards and harmonized approaches to enable the responsible, voluntary, and secure sharing of genomic and clinical data. Learn more at: http://genomicsandhealth.org.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-alliance-for-genomics-and-health-members-meet-to-advance-genomic-data-sharing-359076689.html
SOURCE Global Alliance for Genomics and Health; Broad Institute
Venture capital funding for startups in the San Diego area ticked up slightly during the third quarter that ended Sept. 30, with $238.5 million invested in 27 deals, according to data from the…
[[Click headline to continue reading.]]
Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques
SAN JOSE, Calif., Oct. 20, 2014 /PRNewswire/ — The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia partnership with the United States Air Force Research Laboratory (AFRL), has chosen a project proposed by the Arizona Center for Integrative Medicine (AzCIM) at the University of Arizona College of Medicine – Tucson, to receive research funding. The AzCIM project’s goal is to assess different sweat collection methods and devices for their ability to collect different volumes of sweat under a variety of human-body conditions, the results of which will help determine the best method for integrating into a wearable sensor system. Funding for the one year program will total $200,000.
As part of the project, at least one analytical method, including offline immunoassay or mass spectrometry-based, will be developed to determine the levels of each of several AFRL-preferred biomarkers in sweat samples collected from multiple skin regions. Two molecules, one small and one large protein, will be selected for analysis from the following biomarkers: Orexin-A (impacts arousal and alertness); Neuropeptide Y (associated functions include stress reduction and lowering pain perception); Interleukin 6 (stimulates immune response); cortisol (released in response to stress); and Oxytocin (associated with various reproductive and bonding functions).
Because the biomarker levels may be low and thus more difficult to detect by some analytical techniques, different methods for sweat concentration and purification will also be assessed. The various sweat collection methods will then be assessed for the desired volume, under a variety of conditions, including whole-body hyperthermia.
Esther Sternberg, M.D., project technical lead and AzCIM director of research, noted, “Participating in this program is a natural extension of AzCIM’s research focus on mind-body science. Brain-immune connections are critical in decision-making and alertness, which can be greatly compromised by stress and fatigue, particularly for military personnel and others in high-pressure situations. Trauma related immune activation can also directly compromise performance and brain function. Devising a way to accurately detect these parameters in real time before problems set in, is essential to helping ensure physical and mental wellness for these individuals.”
In addition to Dr. Sternberg, the AzCIM project team includes Min Jia, Ph.D., AzCIM research assistant professor, as alternate technical representative. The AFRL program manager for the project is Laura Rea.
“Reproducibly collecting and analyzing sweat in a range of conditions and scenarios is a central challenge of enabling human performance monitoring,” said Dr. Benjamin Leever, AFRL Lead for Additive Manufacturing of Functional Materials. “This capability could significantly impact a large variety of Air Force missions.”
“AzCIM and Dr. Sternberg possess a sterling reputation for successful collaboration on initiatives that investigate the relationship between wellness and one’s environment,” said NBMC CEO Malcolm Thompson. “Ensuring that we are looking at the right biomarkers and collecting samples in the most optimal manner provides a crucial foundation for helping achieve NBMC’s objective to develop a technology platform for a lightweight, low-cost, wearable biosensor patch.”
About NBMC The Nano-Bio Manufacturing Consortium (NBMC) was formed by the FlexTech Alliance, in collaboration with a nationwide group of partners, for the U.S. Air Force Research Laboratory (AFRL). The mission of the partnership is to bring together leading scientists, engineers, and business development professionals from industry and universities in order to work collaboratively in a consortium, and to mature an integrated suite of nano-bio manufacturing technologies to transition to industrial manufacturing. Initial activities focus on AFRL/ DoD priorities, e.g., physiological readiness and human performance monitoring. Specifically, NBMC matures nano-bio manufacturing technologies to create an integrated suite of reconfigurable and digitized fabrication methods that are compatible with biological and nanoparticle materials and to transition thin film, mechanically compliant device concepts through a foundry-like manufacturing flow. The long-term vision is that NBMC operates at the confluence of four core emerging disciplines: nanotechnology, biotechnology, advanced (additive) manufacturing, and flexible electronics. The convergence of these disparate fields enables advanced sensor architectures for real-time, remote physiological and health/medical monitoring.
SOURCE Nano-Bio Manufacturing Consortium
QIAGEN N.V. Demonstrates Expanded Bioinformatics Workflows At American Society of Human Genetics; Strong Market Adoption As Researchers Analyze Genomic Data On More Than A Quarter-Million Samples In Secure Private Cloud
SAN DIEGO and HILDEN, Germany, October 17, 2014 /PRNewswire/ — Translational research in cancer and other diseases will benefit from new capabilities being presented at the American Society of Human Genetics annual meeting Volume of 250,000-plus DNA samples linked to Ingenuity Knowledge Base greatly exceeds any comparable database – providing superior depth for genomic…
Amicus Therapeutics, Inc. Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011
Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR) Additional GL-3 Data Further Validate Assay for Identifying Patients with Amenable Mutations
Affymetrix (Santa Clara, California) Exclusively Licenses Technology From For HLA Typing From Genotyping Data
SANTA CLARA, Calif.–(BUSINESS WIRE)–Affymetrix (NASDAQ:AFFX) announced today that it has exclusively licensed technology from Peptide Groove LLP that enables HLA typing of human samples from genotyping data generated from a variety of assays including the company’s Axiom genotyping assays. The partners at Peptide Groove LLP developed HLA*IMP, the first HLA typing statistical imputation method which…
Neothetics, a biotech targeting fat reduction with an injectable formulation of an approved asthma drug, filed on Friday with the SEC to raise up to $63 million in an initial public offering.BusinessThe company has completed Phase 2 trials for LIPO-202, its lead candidate that is intended to reduce “subcutaneous fat in the central abdomen that is often characterized by people…
CytRx Corporation Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed
LOS ANGELES, Oct. 20, 2014 /PRNewswire/ –CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled “A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma,” has been published online in Cancer, the prestigious…
Apricus Biosciences Expands Development Pipeline With The In-Licensing Of U.S. Rights For Fispemifene, A Phase 2b Ready Asset, From Targeting Urological Conditions In Men
– Apricus Funds Upfront License Fee and 2015 Phase 2b Development Cost with $10 Million Venture Debt Financing — –Conference Call Today, Monday, Oct. 20, at 8:00 a.m. ET– SAN DIEGO, Oct. 20, 2014 (GLOBE NEWSWIRE…
SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –ResMed (NYSE:RMD) today announced the availability of the ResMed Data Exchange program, a comprehensive suite of software and service solutions for home medical equipment (HME) and other health care providers. ResMed Data Exchange offers timely, secure access to…